Alkaline alpha galactosidase for the treatment of fabry disease
AssigneeProtalix Ltd.
InventorsYoseph Shaaltiel, Tehila Ben-Moshe, Yaniv Azulay
Life of this patent
Estimating the term…
Abstract
A method of treating Fabry is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.
Claims22
A method of treating Fabry disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of alkaline alpha galactosidase, thereby treating Fabry disease.
A pharmaceutical composition comprising as an active ingredient alkaline alpha galactosidase and a pharmaceutically acceptable carrier.
A method of treating Fabry disease in a subject treated with acid alpha galactosidase, the method comprising administering to the subject a therapeutically effective amount of alkaline alpha galactosidase following said treatment with acid alpha galactosidase, thereby treating Fabry disease.
4-5. (canceled)
Dependencies are inferred from the claim text.